Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often and more quickly on sparsentan (Filspari) than irbesartan (Avapro), secondary analyses ...

Additionally, individuals taking medications that affect protein metabolism or those with ... speak with a healthcare professional to determine the best approach for your needs.

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...

of Korea University College of Medicine and Anam Hospital in Seoul, Korea, and colleagues reported in the Journal of the American Heart Association. Proteinuria of 3+ (300 mg/dL) or 4+ (1000 mg/dL ...

The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...